Analysts have been eager to weigh in on the Healthcare sector with new ratings on Merus (MRUS – Research Report), Exelixis (EXEL – Research Report) and Sanofi (SNYNF – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Merus (MRUS)
In a report issued on October 4, Matt Phipps from William Blair maintained a Hold rating on Merus. The company’s shares closed last Wednesday at $94.38.
According to TipRanks.com, Phipps is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Merus with a $97.71 average price target, a 3.5% upside from current levels. In a report issued on September 26, Truist Financial also downgraded the stock to Hold with a $97.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Exelixis (EXEL)
In a report issued on October 4, Andy Hsieh from William Blair maintained a Buy rating on Exelixis. The company’s shares closed last Wednesday at $38.64, close to its 52-week high of $40.02.
According to TipRanks.com, Hsieh is a 4-star analyst with an average return of
Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $43.57, implying a 10.5% upside from current levels. In a report issued on September 25, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $44.00 price target.
Sanofi (SNYNF)
In a report released yesterday, David Risinger from Leerink Partners maintained a Buy rating on Sanofi, with a price target of EUR92.00. The company’s shares closed last Wednesday at $96.64.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Currently, the analyst consensus on Sanofi is a Strong Buy with an average price target of $121.89, representing a 26.1% upside. In a report issued on September 24, Deutsche Bank also maintained a Buy rating on the stock with a EUR110.00 price target.
Read More on MRUS:
Disclaimer & DisclosureReport an Issue
- Genmab price target raised to $49 from $46 at Truist
- Merus downgraded to Market Perform from Outperform at Leerink
- Unusually active option classes on open October 2nd
- Balanced Hold Rating Amid Genmab’s Acquisition of Merus and Anticipated CRC Data
- Hold Rating on Genmab’s Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
